loading
L
O
A
D
I
N
G
Design

In System One, we engineered plasmid pSIP403-N-acyltransferase-PnisA-nisRK-erY, into which the gene encoding the pivotal enzyme N-acyltransferase was incorporated. This modification allowed the plasmid to facilitate the expression of ferrichrome, which subsequently binds to anti-GAD within the human body, thereby reducing the concentration of anti-GAD. This reduction in anti-GAD levels is aimed at achieving therapeutic effects for autism.

In System Two, we designed plasmid pSIP403-hemA-PnisA-nisRK-erY, wherein the hemA gene was inserted. This alteration enabled the plasmid to express protoporphyrin, which binds to anti-MBP within the human body, consequently leading to a decrease in anti-MBP concentration. The intended outcome of this reduction is the treatment of autism.

  • System 1
  • System 2

◈ferrichrome◈

In System One, our objective is to enhance the expression of ferrichrome. This enhancement facilitates the binding of anti-GAD within the brain to ferrichrome, consequently reducing the levels of anti-GAD expression in the patient's cerebral system.

We choose Lactobacillus Plantarum L168 as the chassis and pSIP403 as the vector, and search its synthetic pathway and find the key enzyme N-acyltransferase. Then, we inserted the genes of N-acyltransferase into our designed plasmids to complete the construction and synthesis of plasmids.

system 1

◈protoporphyrin◈

For anti-MBP, we selected protoporphyrin as the small molecule metabolite for antibody degradation. During our investigation, we identified the rate-limiting enzyme, glutamyl-tRNA reductase, within the synthetic pathway.

We identified the gene sequence hemA, encoding the key enzyme glutamyl-tRNA reductase, and designed both upstream and downstream primers for hemA. The selected vector for this purpose was pSIP403. Subsequently, we designed the pSIP403-hemA-PnisA-nisRK-erY plasmid and introduced it into the sensory Lactobacillus plantarum L168. As an additional safety measure, we incorporated a suicide switch that could be activated by a transferable nisin-controlled expression (NICE) system, utilizing the combination of the nisA promoter and nisRK regulatory genes.

system 2(protoporphyrin)

In general, if probiotics want to colonize the intestine, they must first pass through harsh conditions such as gastric and pancreatic juices to increase the number of viable bacteria that reach the small intestine. Therefore, the bioavailability of probiotics can be significantly increased through the use of suitable delivery techniques, such as microencapsulation of probiotics with suitable materials. The so-called microencapsulation is that animal and plant cells are wrapped in beaded microcapsules, preventing enzymes and other biological macromolecules and cells from escaping but allowing tiny molecules and medium-sized nutrients to freely enter the microcapsules, so as to achieve the aim of culture and protection. According to studies, calcium alginate has been widely utilized for the microencapsulation of live bacteria since it is inexpensive, non-toxic, and simple to apply$^2$$^0$. When sodium alginate encounters divalent cations (such as Ca 2+), its phase changes from liquid to cross-linked gel particles. However, alginate beads are not highly resistant to acid, and although they can complete the release of probiotics in the small intestine, they sacrifice a portion of the probiotics' protective ability in gastric acid.

To increase alginate's resilience to acidic environments, we decided to add whey protein, a combination of globular proteins extracted from whey. These proteins are partially resistant to pepsin digestion and shield probiotics prior to their delivery to the target site. Several research have demonstrated that whey protein can be used as an encapsulating material to improve the physical and chemical stability of alginate particles.The pellet proved capable of preserving probiotic activity after a three-hour in vitro incubation in simulated gastric juice$^2$$^1$. Therefore, in order to further improve the survival rate of bacteria in gastric juice, pancreatic juice, and other digestive fluids, we decided, based on the alginate encapsulation of probiotics, to use freeze-drying technology to coat probiotics with whey protein. When the cells are encapsulated, yogurt can be a good carrier of probiotics. Protected bacteria that are alive at the time of consumption will survive through the gastrointestinal tract and reach the intestine in a viable state.

pic: pattern of system 3

◈Principle◈

To detect the mitochondrial function of autistic children, we select lactate as the biosensor. When mitochondrial dysfunction occurs, the activity of pyruvate dehydrogenase is inhibited, and pyruvate cannot enter the tricarboxylic acid cycle. Insufficient ATP production inhibits the activity of pyruvate carboxylase, hence inhibiting gluconeogenesis. Consequently, huge quantities of pyruvate are converted to lactate, resulting in a large increase in the concentration of lactate in the body, which leads to a significant increase in lactate in the urine. A study indicated that lactate is a good biomarker in clinical biochemical metabolites in children with ASD$^2$$^2$. Significant elevations in lactate have also been documented in the urine of autistic children$^2$$^3$.

Currently, numerous lactate detection devices have been created. The majority of them include enzymatic reactions involving lactate oxidase and lactate dehydrogenase connected to amperometric detection or electrochemical biohybrid oxygen sensing based on natural bacteria metabolism. However, many biosensing technologies are either insensitive or expensive, limiting their application and adoption$^2$$^4$.

To detect lactate concentrations, we constructed a whole-cell biosensor primarily mainly include the lldPRD operon. Studies have shown that the lldPRD operon of Escherichia coli is involved in L-lactate metabolism, which is induced by the growth of this compound. The lldPRD operon (formerly named lct) of Escherichia coli is responsible for aerobic l-lactate metabolism. It consists of three genes that form a single transcription unit that can be induced to initiate in L-lactic acid, the lldR gene of which encodes the regulatory protein lldR. Regulatory protein LldR regulates lactate metabolism mainly through its dual effects, that is, lldPRD is an inhibitor or activator. Studies have reported that LldR binds O1 and O2 in the absence of L-lactate, which may lead to DNA loops and transcriptional repression. Binding of L-lactate to LldR promotes conformational changes that may disrupt DNA loops, thereby forming transcriptional open complexes$^2$$^5$.

pic: pattern of system 4

◈Gene circuits◈

We chose Escherichia coli DH5α as the chassis and pSB4K5 as the vector. Constitutively, P9 promoter initiated the expression of lldR. When lactate is introduced, it can bind to the lldR and activate the P11 promoter24, allowing the transcription of the lacZ reporter gene, whose transcript product is β-Galactosidases. On the test strip, X-gal reacted with β-Galactosidases to create an insoluble blue product, causing a color shift.

On the test paper, the immobilized galactoside reacted with -Galactosidases to create an insoluble blue product, causing a color shift.

pic: gene circuits of system 4

1.Meltzer A, Van de Water J. The Role of the Immune System in Autism Spectrum Disorder. Neuropsychopharmacology. 2017 Jan;42(1):284-298. doi: 10.1038/npp.2016.158. Epub 2016 Aug 18. PMID: 27534269; PMCID: PMC5143489.

2.Meltzer A, Van de Water J. The Role of the Immune System in Autism Spectrum Disorder. Neuropsychopharmacology. 2017 Jan;42(1):284-298. doi: 10.1038/npp.2016.158. Epub 2016 Aug 18. PMID: 27534269; PMCID: PMC5143489.

3.Mostafa GA, Al-Ayadhi LY. Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the disease severity. J Neuroinflammation. 2011 Apr 25;8:39.

4.Hughes HK, Mills Ko E, Rose D, Ashwood P. Immune Dysfunction and Autoimmunity as Pathological Mechanisms in Autism Spectrum Disorders. Front Cell Neurosci. 2018 Nov 13;12:405. doi: 10.3389/fncel.2018.00405. PMID: 30483058; PMCID: PMC6242891.

5.Mostafa GA, Al-Ayadhi LY. Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the disease severity. J Neuroinflammation. 2011 Apr 25;8:39.

6.Yang X, Liang S, Wang L, Han P, Jiang X, Wang J, Hao Y, Wu L. Sialic acid and anti-ganglioside antibody levels in children with autism spectrum disorders. Brain Res. 2018 Jan 1;1678:273-277. doi: 10.1016/j.brainres.2017.10.027. Epub 2017 Nov 2. PMID: 29102779.

7.Ashaat EA, Sabry S, Zaki ME, Mohamed R, Abdelsattar HA, Bawady SA, Ashaat NA, Elnaggar W, Ganem MMF, El-Hariri HM, El-Bassyouni HT, Saleh DA. Sialic acid and anti-ganglioside M1 antibodies are invaluable biomarkers correlated with the severity of autism spectrum disorder. Brain Dev. 2023 Apr;45(4):212-219. doi: 10.1016/j.braindev.2022.11.006. Epub 2022 Dec 13. PMID: 36522215.

8.Zhang G, Massaad CA, Gao T, Pillai L, Bogdanova N, Ghauri S, Sheikh KA. Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury. Exp Neurol. 2016 Aug;282:49-55. doi: 10.1016/j.expneurol.2016.05.020. Epub 2016 May 18. PMID: 27208700; PMCID: PMC5351292.

9.Willison HJ, O'Hanlon G, Paterson G, O'Leary CP, Veitch J, Wilson G, Roberts M, Tang T, Vincent A. Mechanisms of action of anti-GM1 and anti-GQ1b ganglioside antibodies in Guillain-Barré syndrome. J Infect Dis. 1997 Dec;176 Suppl 2:S144-9. doi: 10.1086/513799. PMID: 9396699.

10.Aslan C, Konuşkan B, Şener B, Ünal F. Comparison of serum anti-neuronal antibody levels in patients having autism spectrum disorder with and without regression. Turk J Pediatr. 2021;63(5):780-789. doi: 10.24953/turkjped.2021.05.006. PMID: 34738360.

11.Mostafa GA, Al-Ayadhi LY. A lack of association between hyperserotonemia and the increased frequency of serum anti-myelin basic protein auto-antibodies in autistic children. J Neuroinflammation. 2011 Jun 22;8:71. doi: 10.1186/1742-2094-8-71. PMID: 21696608; PMCID: PMC3142225.

12.Rout UK, Dhossche DM. A pathogenetic model of autism involving Purkinje cell loss through anti-GAD antibodies. Med Hypotheses. 2008 Aug;71(2):218-21. doi: 10.1016/j.mehy.2007.11.012. Epub 2008 Jun 2. PMID: 18514431.

13.Manto M, Mitoma H, Hampe CS. Anti-GAD Antibodies and the Cerebellum: Where Do We Stand? Cerebellum. 2019 Apr;18(2):153-156. doi: 10.1007/s12311-018-0986-6. PMID: 30343467; PMCID: PMC6443918.

14.Butler MH, Solimena M, Dirkx R Jr, et al. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993; 178: 2097–2106.